<DOC>
	<DOC>NCT01263028</DOC>
	<brief_summary>Hypothesis: The supplementation of Ergocalciferol (Vitamin D2) to those with Vitamin D deficiency in the Chronic Kidney Disease population requiring recombinant human erythropoietin for the treatment of anemia related to kidney disease will reduce the dose of erythropoietin required to maintain a nonanemic state.</brief_summary>
	<brief_title>Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Chronic kidney disease Age: &gt;18yo Stable Hemoglobin (Hgb) for 1 month on stable dose of erythropoietin for 1 month (defined as erythropoietin dose within 15% of previous months erythropoietin dose) Unchanged maintenance oral or intravenous (IV) iron therapy for 1 month Serum 25hydroxy Vitamin D levels &lt; 30 ng/mL History of 25hydroxy Vitamin D levels &lt; 30 ng/mL currently on ergocalciferol replacement On hemodialysis Chronic kidney disease 5 Hypercalcemic (Calcium level &gt; 11mg/dL) Pregnant female Iron deficient (iron saturation &lt; 20%, Ferritin &lt; 100ng/mL) Presence of active malignancy Presence of active infections Presence of active inflammatory properties Presence of blood dyscrasias Active bleeding or bleeding within the past 3 months (other than menses) B12 deficiency Folate deficiency Blood transfusion during participation Parathyroid levels exceeding the expected levels allowed for the stage of a subjects Chronic kidney disease (Target Parathyroid in: Chronic kidney disease 3 3570 pg/mL, Chronic kidney disease 4 70110 pg/mL)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>